Topic summary

Follow-up: How compounding permissions changed when supply normalised

Sourcing › Regulatory MHRA personal import research use only

This is a generated summary. It shows the 9 most-liked posts from a topic of 78, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

WendelboeTL2Member16 Jul 2026#28

lyophil_margin, post #10: Building on post #9 rather than restating it. If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category. I would put a moderate confidence on that and no more. Go to post

Where the compounding permissions reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.

26 likes in reply to #10 12d

h.bakkerTL218 Jul 2026#36

Post #34 and I disagree about the size of the effect, not about the direction.

On compounding permissions: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

28 likes 10d

r.friskTL220 Jul 2026#44

This follows post #43 rather than contradicting it.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

31 likes 8d

KForsbergTL2Member20 Jul 2026#48

Taking post #47 at face value and following it one step further.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

A modest claim, modestly supported.

23 likes 7d

s.hartmannTL221 Jul 2026#49

Where I part company with post #47, and it is a narrow parting.

Compounding permissions is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.

30 likes 7d

KStephanopoulosTL3Regular22 Jul 2026 · edited#56

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

I have separated what I observed from what I concluded, which does not always happen.

24 likes 6d

me.eriksenTL225 Jul 2026#68

d.fontaine, post #62: Understood, and I withdraw the assumption I opened with. Go to post

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

A qualification I should have led with rather than closed on.

28 likes in reply to #62 3d

f.petrovTL225 Jul 2026#72

k.salinas, post #67: Where I part company with post #65, and it is a narrow parting. Two things can be true about compounding permissions at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second. Go to post

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

22 likes in reply to #67 3d

y.ramosTL226 Jul 2026#76

m.perrin, post #63: Post #60 put the caveat in the right place and I want to underline it. Worth separating compounding permissions as a question about the compound from compounding permissions as a question about the documentation. They get answered by different people and only one of them is answerable here. Go to post

Helpful, and short, which on this subject is harder than long.

29 likes in reply to #63 2d

Read the full topic (78 posts)

This topic was referenced in

Import rules for personal quantities, by jurisdiction, datedSourcing › Regulatory · 3 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Research-use-only labelling: what it means and what it does not — the long version Sourcing › Regulatory EMA research use only compounding Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. A labelling question, and I would like…	+150	158	55k	14mo
Labelling requirements for research chemicals — the long version Sourcing › Regulatory MHRA research use only compounding personal import Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…		2	1.8k	2mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Sourcing › Regulatory MHRA research use only compounding Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…	+50	56	780	8mo
Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA MHRA research use only EMA Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about compound…	+72	78	23k	3mo
Labelling requirements for research chemicals Sourcing › Regulatory research use only MHRA FDA Under review Labelling requirements for research chemicals — setting out what I have, and where I think it stops being reliable. The question about labelling requirements for research chemicals that I actually want…	+5	9	45k	4mo

Related topics — sharing the tags MHRA, personal import, research use only

Topic	Participants	Replies	Views	Activity
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…	+28	32	640	13mo
What changed in 2026, by region — does this still hold? Access › International personal import MHRA EMA telehealth Solved What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…	+20	25	50k	1d
Availability by country, dated, with primary sources — one year on Access › International personal import MHRA NHS Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…	+7	11	850	7mo
Revisiting: German, French and Dutch differences, compared Regional › European Union personal import formulary EMA cost per milligram Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. I have spent a fortnight trying to pin German down and I want…	+90	99	32k	9mo
Cross-border purchase rules within the EU Regional › European Union personal import formulary cost per milligram EMA On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. The question about cross-border purchase rules within that I actually want answered is the second…	+45	49	15k	8mo